Esperion Therapeutics (NASDAQ:ESPR) was upgraded by equities research analysts at ValuEngine from a “hold” rating to a “buy” rating in a research note issued to investors on Tuesday, ValuEngine reports.

A number of other equities research analysts have also commented on ESPR. Northland Securities reaffirmed a “buy” rating on shares of Esperion Therapeutics in a research note on Thursday, August 8th. Credit Suisse Group upped their price objective on shares of Esperion Therapeutics from $79.00 to $90.00 and gave the company an “outperform” rating in a research note on Monday, May 6th. BidaskClub lowered shares of Esperion Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Wednesday, July 31st. Citigroup set a $73.00 price objective on shares of Esperion Therapeutics and gave the company a “buy” rating in a research note on Tuesday, May 28th. Finally, Bank of America raised shares of Esperion Therapeutics from an “underperform” rating to a “neutral” rating in a research note on Monday, May 6th. Three investment analysts have rated the stock with a sell rating, three have issued a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Esperion Therapeutics presently has an average rating of “Hold” and a consensus price target of $74.00.

ESPR traded up $0.62 during trading on Tuesday, reaching $37.61. 286,247 shares of the company’s stock were exchanged, compared to its average volume of 548,495. Esperion Therapeutics has a one year low of $36.06 and a one year high of $60.99. The stock has a market capitalization of $1.01 billion, a PE ratio of -4.99 and a beta of 1.67. The stock has a fifty day moving average price of $43.23.

Esperion Therapeutics (NASDAQ:ESPR) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($2.01) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.86) by ($0.15). The firm had revenue of $0.98 million for the quarter, compared to the consensus estimate of $1.05 million. During the same quarter in the prior year, the company posted ($1.71) earnings per share. The business’s revenue was up 9720.0% on a year-over-year basis. On average, sell-side analysts expect that Esperion Therapeutics will post -2.56 EPS for the current year.

In related news, CEO Timothy M. Mayleben bought 5,000 shares of the company’s stock in a transaction that occurred on Friday, June 28th. The shares were bought at an average price of $46.00 per share, for a total transaction of $230,000.00. Following the transaction, the chief executive officer now directly owns 66,163 shares of the company’s stock, valued at $3,043,498. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, major shareholder Target N. V. Biotech bought 50,000 shares of the company’s stock in a transaction that occurred on Tuesday, July 23rd. The shares were bought at an average price of $42.65 per share, for a total transaction of $2,132,500.00. Following the transaction, the insider now directly owns 3,572,964 shares in the company, valued at $152,386,914.60. The disclosure for this purchase can be found here. Insiders have purchased a total of 60,000 shares of company stock worth $2,560,300 in the last quarter. 7.70% of the stock is owned by corporate insiders.

Several institutional investors have recently added to or reduced their stakes in the stock. State Board of Administration of Florida Retirement System lifted its position in shares of Esperion Therapeutics by 2.3% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 11,360 shares of the biopharmaceutical company’s stock valued at $456,000 after acquiring an additional 260 shares during the period. Advisor Group Inc. lifted its position in shares of Esperion Therapeutics by 44.4% during the 4th quarter. Advisor Group Inc. now owns 947 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 291 shares during the period. Aperio Group LLC acquired a new position in shares of Esperion Therapeutics during the 2nd quarter valued at $29,000. Russell Investments Group Ltd. acquired a new position in shares of Esperion Therapeutics during the 2nd quarter valued at $32,000. Finally, Swiss National Bank lifted its position in shares of Esperion Therapeutics by 2.0% during the 2nd quarter. Swiss National Bank now owns 44,900 shares of the biopharmaceutical company’s stock valued at $2,089,000 after acquiring an additional 900 shares during the period.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Recommended Story: What does a bar chart display?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.